Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose

Imagem de Miniatura
Arquivos
art_PEREIRA_AntiSARSCoV2_inactivated_vaccine_in_patients_with_ANCAassociated_vasculitis_.PDF (623.48 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER ESPANA
Autores
Citação
CLINICS, v.78, article ID 100150, 8p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: To evaluate inactivated CoronaVac prime vaccination, antibody decay, booster dose, and safety in ANCA-Associated Vasculitis (AAV) patients.Methods: Fifty-three AAV patients and 106 Controls (CG) received CoronaVac on days: D0 (first dose), D28(second dose), and D210 (booster dose, 32 AAV: 32 CG). The primary outcome was immunogenicity after the second vac-cine dose (day 69) assessed by Seroconversion Rates (SC) of anti-SARS-CoV-2 S1/S2 IgG and Neutralizing Anti-bodies (NAb). Secondary outcomes were safety, immunogenicity (D28/D240), 6-months antibody decay (D210) and the booster dose response (D240).Results: At D69 SC (65.1% vs. 96.8%, p = 0.0001), GMT (21.3 UA/mL vs. 67.7 UA/mL, p < 0.001) and NAb- posi-tivity (53.7% vs. 80.6%, p = 0.001) were moderate but lower in naive-AAV patients than CG. Patients without SC used more often IS (93.3% vs. 53.3%, p = 0.015), mycophenolate mofetil (20% vs. 0%, p = 0.037) and predni-sone (60.0% vs. 28.6%, p = 0.057) than seroconverted. NAb negativity in AAV patients was associated with pred-nisone treatment (57.9% vs. 18.2%, p = 0.015) and IS (84.2% vs. 55.0%, p = 0.046). Logistic regression analysis models showed that only prednisone was associated with lower seroconversion (OR = 0.2, 0,95% CI 0.05-0.86, p = 0.030) and with lower NAb positivity (OR = 0.2, 0,95% CI 0.05-0.88, p = 0.034). After six months (D69 -D210) a decrease in IgG positivity occurred in 32 AAV patients (15.7%, p = 0.074) and 32 CG (18.7%, p = 0.041). For the NAb positivity, the 6-month decrease was not significant (p = 0.114) whereas a major reduc-tion occurred for CG (p < 0.001). A booster dose (D240) resulted in an increment in IgG-positivity (21.9%, p = 0.023) and NAb-positivity (34.4%, p = 0.006) in AAV patients. No moderate/severe adverse events attribut-able to the vaccine were observed.Conclusion: This study provides novel data on the excellent safety and moderate immunogenicity of CoronaVac in AAV patients. A six-month mild antibody waning was observed with a good response to the booster dose, although levels remained lower than CG (CoronavRheum-NCT04754698).
Palavras-chave
ANCA-associated vasculitis, Vaccine, SARS-CoV-2, Immunogenicity
URI
https://observatorio.fm.usp.br/handle/OPI/52881
Referências
  1. Aikawa NE, 2022, LANCET RHEUMATOL, V4, pE113, DOI 10.1016/S2665-9913(21)00327-1
  2. Aikawa NE, 2022, ANN RHEUM DIS, V81, P1036, DOI 10.1136/annrheumdis-2021-222096
  3. Gómez Ana María Autrán, 2020, Int. braz j urol., V46, P3, DOI [10.1590/s1677-5538.ibju.2020.s1ed2, 10.1590/S1677-5538.IBJU.2020.S1ED2]
  4. Bruchfeld A, 2021, NAT REV NEPHROL, V17, P81, DOI 10.1038/s41581-020-00381-4
  5. Bugatti S, 2021, ANN RHEUM DIS, V80, P1635, DOI 10.1136/annrheumdis-2021-220862
  6. Deepak Parakkal, 2021, medRxiv, DOI 10.1101/2021.04.05.21254656
  7. Duran TI, 2021, RHEUMATOL INT, V41, P1523, DOI 10.1007/s00296-021-04914-3
  8. Exley AR, 1997, ARTHRITIS RHEUM, V40, P371, DOI 10.1002/art.1780400222
  9. Friedman MA, 2021, ANN RHEUM DIS, V80, P1255, DOI 10.1136/annrheumdis-2021-221244
  10. Furer V, 2021, ANN RHEUM DIS, V80, P1330, DOI 10.1136/annrheumdis-2021-220647
  11. Gao YD, 2021, ALLERGY, V76, P428, DOI 10.1111/all.14657
  12. Gavriatopoulou M, 2021, CLIN EXP MED, V21, P167, DOI 10.1007/s10238-020-00671-y
  13. Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
  14. Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
  15. Hosseini ES, 2020, VIROLOGY, V551, P1, DOI 10.1016/j.virol.2020.08.011
  16. Ita K, 2021, ARCH MED RES, V52, P15, DOI 10.1016/j.arcmed.2020.09.010
  17. Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715
  18. Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8
  19. Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3
  20. LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807
  21. Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583
  22. Mahil SK, 2021, LANCET RHEUMATOL, V3, pE627, DOI 10.1016/S2665-9913(21)00212-5
  23. MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806
  24. Mbaeyi S., 2021, MMWR-MORBID MORTAL W
  25. Medeiros-Ribeiro AC, 2021, NAT MED, V27, P1744, DOI 10.1038/s41591-021-01469-5
  26. Mukhtyar C, 2009, ANN RHEUM DIS, V68, P1827, DOI 10.1136/ard.2008.101279
  27. Pablos JL, 2020, ANN RHEUM DIS, V79, P1544, DOI 10.1136/annrheumdis-2020-218296
  28. Simon D, 2021, ANN RHEUM DIS, V80, P1312, DOI 10.1136/annrheumdis-2021-220461
  29. Spiera R, 2021, ANN RHEUM DIS, V80, P1357, DOI 10.1136/annrheumdis-2021-220604
  30. Taheri A., 2021, PREPRINT, DOI [10.21203/rs.3.rs-252931/v1, DOI 10.21203/RS.3.RS, 10.21203/rs.3.rs]
  31. Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X
  32. Taylor SC, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02438-20
  33. Tumban E, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010054
  34. World Health Organization, 2021, WHO DRAFT GUID ADV E
  35. Yuki EFN, 2022, ARTHRIT CARE RES, V74, P562, DOI 10.1002/acr.24824

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - HC/InCor
Carregar mais